Boston Scientific · 7 hours ago
Software Development Engineer Intern 2026
Waltham, MA
Internship
Hybrid
Intern
$43K/yr - $74K/yr
Start in 2026Boston Scientific is a leader in medical science, dedicated to solving health industry challenges. The Software Development Engineer Intern will work with a dynamic team to develop and test software applications for the Opal Mapping system, utilizing coding skills in C++, Python, or MATLAB.
Health CareMedicalMedical Device
No H1B
Responsibilities
Design, develop, unit test software applications in C++, Python or MATLAB
Participate in scrum team to coordinate development of new features and resolve issues
Collaborate with team in all aspects of software development
Qualification
Required
Must graduate between Fall 2026 – Spring 2027
Currently pursuing a Bachelor's or a graduate degree in Computer Science, Biomedical Engineering or Electrical Engineering
Must be able to commit to one of the following full internship program periods: May 18th – August 7th OR May 26th – August 14th
Proficiency in coding with C++, Python, or MATLAB
Must have reliable transportation to and from the Boston Scientific Corporate location in Waltham, MA
Must be eligible to work in the U.S. without company sponsorship, now or in the future, for employment-based work authorization
Preferred
Prior software testing experience preferred
Good written and verbal communication skills. General report writing/documentation experience
A natural attention to detail and a penchant for organizing and documenting
A good learner who can master complex software and quickly adapt to new tools and technologies
Ability to work independently as well as work collaboratively as part of a team
Benefits
Relocation assistance may be available to those who meet the eligibility criteria.
Company
Boston Scientific
Boston Scientific is a medical technology company that designs and develops medical devices to diagnose and treat a wide range of condition.
Founded in 1979
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$10.02B2025-02-21Post Ipo Debt· $1.58B
2024-02-22Post Ipo Debt· $2.17B
2022-03-04Post Ipo Debt· $3.28B
Leadership Team
Michael Mahoney
Chairman, President & CEO
Daniel J. Brennan
Chief Financial Officer
Recent News
2026-01-24
2026-01-23
Company data provided by crunchbase